OBJECTIVE: To test the hypothesis that FYN, a member of the SRC family of kinases (SFKs), is up-regulated in prostate cancer, as FYN is functionally distinct from other SFKs, and interacts with FAK and paxillin (PXN), regulators of cell morphology and motility. MATERIALS AND METHODS: Through data-mining in Oncomine (http://www.oncomine.org), cell-line profiling with immunoblotting, quantitative reverse transcription and polymerase chain reaction (RT-PCR) and immunohistochemical analysis, we described FYN expression in prostate cancer. The analysis included 32 cases of prostate cancer, nine of prostatic intraepithelial neoplasia (PIN) and 19 normal prostates. Samples were scored for the percentage of stained glands and intensity of staining (from 0 to 3). Each sample was assigned a composite score generated by multiplying percentage and intensity. RESULTS: Data-mining showed an eight times greater FYN expression in prostate cancer than in normal tissue; this was specific to FYN and not present for other SFKs. Expression of FYN in prostate cancer cell lines (LNCaP, 22Rv1, PC3, DuPro) was detected using quantitative RT-PCR and immunoblotting. Expression of FYN and its signalling partners FAK and PXN was detected in human tissue. Comparing normal with cancer samples, there was a 2.1-fold increase in median composite score for FYN (P < 0.001) 1.7-fold increase in FAK (P < 0.001), and a doubling in PXN (P < 0.05). There was a 1.7-fold increase in FYN (P < 0.05) and a 1.6-fold increase in FAK (P < 0.01) in cancer compared with PIN. CONCLUSIONS: These studies support the hypothesis that FYN and its related signalling partners are up-regulated in prostate cancer, and support further investigation into the role of the FYN as a therapeutic target.
OBJECTIVE: To test the hypothesis that FYN, a member of the SRC family of kinases (SFKs), is up-regulated in prostate cancer, as FYN is functionally distinct from other SFKs, and interacts with FAK and paxillin (PXN), regulators of cell morphology and motility. MATERIALS AND METHODS: Through data-mining in Oncomine (http://www.oncomine.org), cell-line profiling with immunoblotting, quantitative reverse transcription and polymerase chain reaction (RT-PCR) and immunohistochemical analysis, we described FYN expression in prostate cancer. The analysis included 32 cases of prostate cancer, nine of prostatic intraepithelial neoplasia (PIN) and 19 normal prostates. Samples were scored for the percentage of stained glands and intensity of staining (from 0 to 3). Each sample was assigned a composite score generated by multiplying percentage and intensity. RESULTS: Data-mining showed an eight times greater FYN expression in prostate cancer than in normal tissue; this was specific to FYN and not present for other SFKs. Expression of FYN in prostate cancer cell lines (LNCaP, 22Rv1, PC3, DuPro) was detected using quantitative RT-PCR and immunoblotting. Expression of FYN and its signalling partners FAK and PXN was detected in human tissue. Comparing normal with cancer samples, there was a 2.1-fold increase in median composite score for FYN (P < 0.001) 1.7-fold increase in FAK (P < 0.001), and a doubling in PXN (P < 0.05). There was a 1.7-fold increase in FYN (P < 0.05) and a 1.6-fold increase in FAK (P < 0.01) in cancer compared with PIN. CONCLUSIONS: These studies support the hypothesis that FYN and its related signalling partners are up-regulated in prostate cancer, and support further investigation into the role of the FYN as a therapeutic target.
Authors: M Sumitomo; R Shen; M Walburg; J Dai; Y Geng; D Navarro; G Boileau; C N Papandreou; F G Giancotti; B Knudsen; D M Nanus Journal: J Clin Invest Date: 2000-12 Impact factor: 14.808
Authors: Dejan Juric; Norman J Lacayo; Meghan C Ramsey; Janis Racevskis; Peter H Wiernik; Jacob M Rowe; Anthony H Goldstone; Peter J O'Dwyer; Elisabeth Paietta; Branimir I Sikic Journal: J Clin Oncol Date: 2007-02-20 Impact factor: 44.544
Authors: T L Lotan; M Lyon; D Huo; J B Taxy; C Brendler; B A Foster; W Stadler; C W Rinker-Schaeffer Journal: J Pathol Date: 2007-08 Impact factor: 7.996
Authors: Kinga Bednarek; Magdalena Kostrzewska-Poczekaj; Adam Ustaszewski; Joanna Janiszewska; Katarzyna Kiwerska; Julia Paczkowska; Reidar Grenman; Maciej Giefing; Malgorzata Jarmuz-Szymczak Journal: Am J Cancer Res Date: 2021-05-15 Impact factor: 6.166
Authors: Zhaoju Wu; Pei-Ching Chang; Joy C Yang; Cheng-Ying Chu; Ling-Yu Wang; Nien-Tsu Chen; Ai-Hong Ma; Sonal J Desai; Su Hao Lo; Christopher P Evans; Kit S Lam; Hsing-Jien Kung Journal: Genes Cancer Date: 2010-01
Authors: Andreas Varkaris; Anastasia D Katsiampoura; John C Araujo; Gary E Gallick; Paul G Corn Journal: Cancer Metastasis Rev Date: 2014-09 Impact factor: 9.264
Authors: Adam T Szafran; Cliff Stephan; Michael Bolt; Maureen G Mancini; Marco Marcelli; Michael A Mancini Journal: Prostate Date: 2016-10-04 Impact factor: 4.104
Authors: Edwin M Posadas; Rafi S Ahmed; Theodore Karrison; Russell Z Szmulewitz; Peter H O'Donnell; James L Wade; James Shen; Murali Gururajan; Margarit Sievert; Walter M Stadler Journal: Prostate Date: 2015-10-23 Impact factor: 4.104
Authors: Emmanuel S Antonarakis; Elisabeth I Heath; Edwin M Posadas; Evan Y Yu; Michael R Harrison; Justine Y Bruce; Steve Y Cho; Gregory E Wilding; Gerald J Fetterly; David G Hangauer; Min-Fun R Kwan; Lyn M Dyster; Michael A Carducci Journal: Cancer Chemother Pharmacol Date: 2013-01-13 Impact factor: 3.333
Authors: Evan Y Yu; George Wilding; Edwin Posadas; Mitchell Gross; Stephane Culine; Christophe Massard; Michael J Morris; Gary Hudes; Fabio Calabrò; Shinta Cheng; Géralyn C Trudel; Prashni Paliwal; Cora N Sternberg Journal: Clin Cancer Res Date: 2009-11-17 Impact factor: 12.531